公开(公告)号：WO2010111018A8

公开(公告)日：2011-03-03

申请号：PCT/US2010026429

申请日：2010-03-05

Applicant: AGENSYS INC ,  SEATTLE GENETICS INC ,  GUDAS JEAN ,  JAKOBOVITS AYA ,  AN ZILI ,  MORRISON ROBERT KENDALL ,  MORRISON KAREN JANE MEYRICK ,  JIA XIAO-CHI ,  BENJAMIN DENNIS ,  MOSER RUTH ,  SENTER PETER

Inventor： GUDAS JEAN ,  JAKOBOVITS AYA ,  AN ZILI ,  MORRISON ROBERT KENDALL ,  MORRISON KAREN JANE MEYRICK ,  JIA XIAO-CHI ,  BENJAMIN DENNIS ,  MOSER RUTH ,  SENTER PETER

IPC: A61K39/00 ,  C12P21/08

CPC classification number: C07K16/30 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6863 ,  A61K2039/505 ,  C07K16/3046

Abstract: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract translation: 本文描述了结合24P4C12蛋白及其变体的抗体药物偶联物（ADC）。 24P4C12在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，本发明的ADC提供了用于治疗癌症的治疗组合物。

公开(公告)号：WO2005118864A2

公开(公告)日：2005-12-15

申请号：PCT/US2005/017412

申请日：2005-05-17

Applicant: AGENSYS, INC. ,  GUDAS, Jean ,  JAKOBOVITS, Aya ,  JIA, Xiao-chi ,  MORRISON, Robert, Kendall ,  MORRISON, Karen, Jane, Meyrick ,  SHAO, Hui ,  CHALLITA-EID, Pia, M. ,  RAITANO, Arthur, B.

Inventor： GUDAS, Jean ,  JAKOBOVITS, Aya ,  JIA, Xiao-chi ,  MORRISON, Robert, Kendall ,  MORRISON, Karen, Jane, Meyrick ,  SHAO, Hui ,  CHALLITA-EID, Pia, M. ,  RAITANO, Arthur, B.

IPC: C12Q1/68

CPC classification number: C07K14/705 ,  A61K39/00 ,  A61K49/0002 ,  A61K2039/505 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/734 ,  C07K2317/77

Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

Abstract translation: 其中PSCA在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，PSCA提供诊断，预后， 癌症的预防和/或治疗靶标。 PSCA基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与PSCA反应的抗体或T细胞可用于主动或被动免疫。

公开(公告)号：WO2004016769A3

公开(公告)日：2004-10-14

申请号：PCT/US0326232

申请日：2003-08-19

Applicant: ABGENIX INC ,  GUDAS JEAN M ,  HAAK-FRENDSCHO MARY ,  FOORD ORIT ,  LIANG MEINA L ,  AHLUWALIA KIRAN ,  BHAKTA SUNIL

Inventor： GUDAS JEAN M ,  HAAK-FRENDSCHO MARY ,  FOORD ORIT ,  LIANG MEINA L ,  AHLUWALIA KIRAN ,  BHAKTA SUNIL

IPC: G01N33/53 ,  A61K39/395 ,  A61P9/10 ,  A61P13/12 ,  A61P17/06 ,  A61P19/02 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P43/00 ,  C07K16/00 ,  C07K16/24 ,  C07K17/00 ,  C12N15/09 ,  C12P21/08

CPC classification number: C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565

Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Abstract translation: 本文描述的本发明的实施方案涉及针对抗原单核细胞化学引诱物蛋白-1（MCP-1）的抗体和这种抗体的用途。 特别地，根据一些实施方案，提供针对抗原MCP-1的完全人单克隆抗体。 编码Nuclotide序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 ，提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

公开(公告)号：WO2005012479A3

公开(公告)日：2006-10-12

申请号：PCT/US2004020564

申请日：2004-06-25

Applicant: ABGENIX INC ,  WEBER RICHARD ,  FENG XIAO ,  FOORD ORIT ,  GREEN LARRY ,  GUDAS JEAN ,  KEYT BRUCE ,  LIU YING ,  RATHANASWAMI PALANI ,  RAYA ROBERT ,  YANG XIAO DONG ,  CORVALAN JOSE ,  FOLTZ IAN ,  JIA XIAO-CHI ,  KANG JASPAL ,  KING CHADWICK T ,  KLAKAMP SCOTT L ,  SU QIAOJUAN JANE

Inventor： WEBER RICHARD ,  FENG XIAO ,  FOORD ORIT ,  GREEN LARRY ,  GUDAS JEAN ,  KEYT BRUCE ,  LIU YING ,  RATHANASWAMI PALANI ,  RAYA ROBERT ,  YANG XIAO DONG ,  CORVALAN JOSE ,  FOLTZ IAN ,  JIA XIAO-CHI ,  KANG JASPAL ,  KING CHADWICK T ,  KLAKAMP SCOTT L ,  SU QIAOJUAN JANE

IPC: C07K16/28 ,  A61K39/395 ,  A61K39/44 ,  A61K47/48 ,  C07H21/04 ,  C07K14/71 ,  C07K16/22 ,  C07K16/42 ,  C07K17/00 ,  C12N20060101 ,  C12N5/06 ,  C12N5/12 ,  C12P21/08 ,  G01N33/53 ,  G01N33/552 ,  G01N33/577

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体的缺失突变体的抗体，特别涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体，特别是EGFRvIII的缺失突变体的人单克隆抗体。 还提供了这种抗体的诊断和治疗制剂及其免疫偶联物。

公开(公告)号：WO2005113601A2

公开(公告)日：2005-12-01

申请号：PCT/US2004/012625

申请日：2004-04-22

Applicant: AGENSYS, INC. ,  JAKOBOVITS, Aya ,  ETESSAMI, Soudabeh ,  CHALLITA-EID, Pia, M. ,  PEREZ-VILLAR, Juan, J. ,  MORRISON, Karen, J. ,  JIA, Xiao-Chi ,  FARIS, Mary ,  GUDAS, Jean ,  RAITANO, Arthur, B.

Inventor： JAKOBOVITS, Aya ,  ETESSAMI, Soudabeh ,  CHALLITA-EID, Pia, M. ,  PEREZ-VILLAR, Juan, J. ,  MORRISON, Karen, J. ,  JIA, Xiao-Chi ,  FARIS, Mary ,  GUDAS, Jean ,  RAITANO, Arthur, B.

IPC: C07K16/00

CPC classification number: C07K16/40 ,  A61K39/39533 ,  A61K45/06 ,  A61K47/48607 ,  A61K47/6861 ,  A61K51/106 ,  A61K51/1075 ,  A61K2039/505 ,  C07H21/04 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/565 ,  G01N33/6887 ,  A61K2300/00

Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.

Abstract translation: 其中描述了结合新型STEAP-1蛋白的抗体和衍生自其的变体及其变体，其中STEAP-1在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，STEAP-1 提供癌症的诊断，预后，预防和/或治疗靶标。 STEAP-1基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与STEAP-1反应的抗体或T细胞可用于主动或被动免疫。

公开(公告)号：WO2005010151A3

公开(公告)日：2005-02-03

申请号：PCT/US2004/020295

申请日：2004-06-25

Applicant: ABGENIX, INC ,  WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

Inventor： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC: A61K39/395

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

公开(公告)号：WO2012047724A1

公开(公告)日：2012-04-12

申请号：PCT/US2011/054054

申请日：2011-09-29

Applicant: AGENSYS, INC. ,  SEATTLE GENETICS, INC. ,  SATPAEV, Daulet ,  MORRISON, Robert, Kendall ,  MORRISON, Karen Jane, Meyrick ,  GUDAS, Jean ,  JAKOBOVITS, Aya ,  TORGOV, Michael ,  AN, Zili

Inventor： SATPAEV, Daulet ,  MORRISON, Robert, Kendall ,  MORRISON, Karen Jane, Meyrick ,  GUDAS, Jean ,  JAKOBOVITS, Aya ,  TORGOV, Michael ,  AN, Zili

IPC: A61K39/00 ,  A61K39/395 ,  C07K1/00

CPC classification number: A61K47/6851 ,  A61K47/6801 ,  A61K47/6803 ,  A61K47/6811 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6859 ,  A61K47/6861 ,  A61K47/6889 ,  A61K2039/505 ,  A61N5/1001 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3038 ,  C07K2317/14 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/92

Abstract: Antibody drug conjugates (ADC's) that bind to 191P4D12 protein and variants thereof are described herein. 191P4D12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.

Abstract translation: 本文描述了与191P4D12蛋白及其变体结合的抗体药物偶联物（ADC's）。 191P4D12在正常成人组织中表现出组织特异性表达，并且在表I中列出的癌症中异常表达。因此，本发明的ADC提供了用于治疗癌症的治疗组合物。

公开(公告)号：WO2006105488A3

公开(公告)日：2006-10-05

申请号：PCT/US2006/012314

申请日：2006-03-31

Applicant: AGENSYS, INC. ,  JAKOBOVITS, Aya ,  KANNER, Steven, B. ,  CHALLITA-EID, Pia, M. ,  PEREZ-VILLAR, Juan, J. ,  SATPAEV, Daulet ,  RAITANO, Arthur, B. ,  MORRISON, Robert, Kendall ,  MORRISON, Karen, Jane, Meyrick ,  JIA, Xiao-chi ,  GUDAS, Jean

Inventor： JAKOBOVITS, Aya ,  KANNER, Steven, B. ,  CHALLITA-EID, Pia, M. ,  PEREZ-VILLAR, Juan, J. ,  SATPAEV, Daulet ,  RAITANO, Arthur, B. ,  MORRISON, Robert, Kendall ,  MORRISON, Karen, Jane, Meyrick ,  JIA, Xiao-chi ,  GUDAS, Jean

IPC: A61K38/00 ,  A61K39/395 ,  A61K49/00 ,  G01N33/53 ,  C12N15/00 ,  C07H21/04

Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

公开(公告)号：WO2006105488A2

公开(公告)日：2006-10-05

申请号：PCT/US2006012314

申请日：2006-03-31

Applicant: AGENSYS INC ,  JAKOBOVITS AYA ,  KANNER STEVEN B ,  CHALLITA-EID PIA M ,  PEREZ-VILLAR JUAN J ,  SATPAEV DAULET ,  RAITANO ARTHUR B ,  MORRISON ROBERT KENDALL ,  MORRISON KAREN JANE MEYRICK ,  JIA XIAO-CHI ,  GUDAS JEAN

Inventor： JAKOBOVITS AYA ,  KANNER STEVEN B ,  CHALLITA-EID PIA M ,  PEREZ-VILLAR JUAN J ,  SATPAEV DAULET ,  RAITANO ARTHUR B ,  MORRISON ROBERT KENDALL ,  MORRISON KAREN JANE MEYRICK ,  JIA XIAO-CHI ,  GUDAS JEAN

IPC: C07K16/30

CPC classification number: C07K16/30 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/73

Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

Abstract translation: 其中161P2F10B在正常成人组织中表现出组织特异性表达，并且在表I所示的癌症中异常表达。因此，161P2F10B提供诊断，预后，预防和 /或癌症治疗靶标。 161P2F10B基因或其片段或其编码的蛋白质或其变体或其片段可用于引发体液或细胞免疫应答; 与161P2F10B反应的抗体或T细胞可用于主动或被动免疫。

公开(公告)号：WO2005012479A2

公开(公告)日：2005-02-10

申请号：PCT/US2004/020564

申请日：2004-06-25

Applicant: ABGENIX, INC ,  WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

Inventor： WEBER, Richard ,  FENG, Xiao ,  FOORD, Orit ,  GREEN, Larry ,  GUDAS, Jean ,  KEYT, Bruce ,  LIU, Ying ,  RATHANASWAMI, Palani ,  RAYA, Robert ,  YANG, Xiao, Dong ,  CORVALAN, Jose ,  FOLTZ, Ian ,  JIA, Xiao-Chi ,  KANG, Jaspal ,  KING, Chadwick, T. ,  KLAKAMP, Scott, L. ,  SU, Qiaojuan, Jane

IPC: C12N

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/77 ,  C07K2317/92 ,  Y10S435/81

Abstract: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Abstract translation: 本发明涉及新型抗体，特别是针对表皮生长因子受体缺失突变体的抗体，特别是涉及III型缺失突变体EGFRvIII的抗体。 本发明还涉及针对表皮生长因子受体缺失突变体特别是EGFRvIII的人单克隆抗体。 还提供了此类抗体的诊断和治疗制剂及其免疫偶联物。